Source link : https://www.newshealth.biz/health-news/brain-edema-risk-may-be-lower-with-modified-donanemab-dosing/
An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer’s disease, the phase IIIb TRAILBLAZER-ALZ 6 study showed. At week 24, the frequency of amyloid-related imaging abnormalities with edema and effusion (ARIA-E) was 23.7% for the standard dosing […]
Author : News Health
Publish date : 2024-10-29 21:15:14
Copyright for syndicated content belongs to the linked Source.